Parabilis Medicines, Inc.
- PBLS ยท Nasdaq
- Pharmaceutical Preparations
- Cambridge, MA
- CIK 0001657677
Updated from SEC filings through
Top things to know
Executives
- Mathai Mammen President & CEO Form 3, June 9, 2026
- Thomas Rodolpho Kotarakos Chief Financial Officer Form 3, June 9, 2026
- Mohammed Fawzi Benzaghou Chief Medical Officer Form 3, June 9, 2026
- Teresa Jurgensen General Counsel Form 3, June 9, 2026
Parabilis Medicines, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Cambridge, MA. It trades as PBLS on Nasdaq.
Five-year financials
We have no annual financials for this company yet.
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Mathai Mammen | President & CEO | Form 3, June 9, 2026 |
| Thomas Rodolpho Kotarakos | Chief Financial Officer | Form 3, June 9, 2026 |
| Mohammed Fawzi Benzaghou | Chief Medical Officer | Form 3, June 9, 2026 |
| Teresa Jurgensen | General Counsel | Form 3, June 9, 2026 |
What Parabilis Medicines, Inc. does
- Innovation - R&D Focus - About Helicons - Platform - Programs - Publications - Patients - Expanded Access Statement - Company - Leadership - How We Got Here - Culture - Investors - Overview - News & Events - News Releases - Events - Presentations - Stock - Stock Quote & Chart - Corporate Governance - Documents & Charters - Leadership - Committee Composition - Financial Information - SEC Filings - Shareholder Services - Investor FAQs - Email Alerts - Contact Us
Company website description, 10-K for the year ending November 7, 2026
Shares and governance
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 12, 2026 |
|---|
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| July 22, 2026 | Capital Management L.P. Ra Director | Buy | 244,593 | $6.9M | Form 4, July 22, 2026 |
| July 22, 2026 | Peter Kolchinsky Director | Buy | 244,593 | $6.9M | Form 4, July 22, 2026 |
| July 22, 2026 | Rajeev M. Shah Director | Buy | 244,593 | $6.9M | Form 4, July 22, 2026 |
| July 22, 2026 | Capital Nexus Fund L.P. RA III Director | Buy | 244,593 | $6.9M | Form 4, July 22, 2026 |
| July 22, 2026 | Capital Healthcare Fund LP RA Director | Buy | 244,593 | $6.9M | Form 4, July 22, 2026 |
| June 15, 2026 | Alan Sebulsky Director | Buy | 17,500 | $474K | Form 4, June 16, 2026 |
| June 11, 2026 | Capital Nexus Fund L.P. RA III Director | Buy | 21,188,750 | $424M | Form 4, June 15, 2026 |
| June 11, 2026 | Capital Healthcare Fund LP RA Director | Buy | 21,188,750 | $424M | Form 4, June 15, 2026 |
Recent 8-K events
- 8-K filed 2026-11-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-11-05
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-09-15
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-09-02
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-08-25
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-13
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-11
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
Frequently asked questions about Parabilis Medicines, Inc.
- What does Parabilis Medicines, Inc. do?
- In its own words, from Item 1 of its 10-K: "- Innovation - R&D Focus - About Helicons - Platform - Programs - Publications - Patients - Expanded Access Statement - Company - Leadership - How We Got Here - Culture - Investors - Overview - News & Events - News Releases - Events - Presentations - Stock - Stock Quote & Chart - Corporate Governance - Documents & Charters - Leadership - Committee Composition - Financial Information - SEC Filings - Shareholder Services - Investor FAQs - Email Alerts - Contact Us"
- Who is the CFO of Parabilis Medicines, Inc.?
- Thomas Rodolpho Kotarakos, Chief Financial Officer, as named in a 3 filed June 9, 2026.
- Where is Parabilis Medicines, Inc. headquartered?
- Cambridge, MA.
- What is Parabilis Medicines, Inc.'s stock ticker?
- PBLS on Nasdaq.
- What industry is Parabilis Medicines, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Parabilis Medicines, Inc.'s website?
- parabilismed.com. Investor relations: https://investors.parabilismed.com/.
- When does Parabilis Medicines, Inc. report earnings next?
- November 30, 2026. Source: sec_8k.
- Is Parabilis Medicines, Inc. a public company?
- Yes. Parabilis Medicines, Inc. files with the SEC under CIK 0001657677 and trades as PBLS.
- How many business segments does Parabilis Medicines, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 12, 2026.
- Have Parabilis Medicines, Inc. insiders traded stock recently?
- Since June 11, 2026, officers and directors reported 0 open-market sales and 12 purchases worth about $2.2B on Forms 4 and 5. The most recent: Capital Management L.P. Ra (Director) bought 244,593 shares on July 22, 2026.